Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
2.
Blood ; 87(12): 5185-95, 1996 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-8652832

RESUMO

Serum reactivities to a panel of phospholipid antigens, including cardiolipin (CL), phosphatidylserine (PS), sphingomyelin, phosphatidylcholine, and phosphatidylethanolamine, were measured by enzyme-linked immunosorbent assay in 196 human immunodeficiency virus-l+ (HIV-1+) patients with CDC II to IVC clinical disease. Significant levels of IgG to CL, PS, or both were observed in 23 patients lacking evidence of thrombophilic events or any peculiar clinical feature of HIV-1 infection. Fluorescence-activated cell sorting analyses showed that in vitro apoptosis of T cells was increased in patients with high serum anti-PS IgG, whereas the overexpression of Fas/Apo-1 marker was detected in all patients regardless of their antiphospholipid reactivities. Macrophages from patients with significant titers of anti-PS IgG antibodies were not activated by the presence of apoptotic CEM lymphoblasts or by purified anti-PS IgG from the same patients. By contrast, these antibodies greatly improved the effector functions of autologous macrophages in antibody-dependent cellular cytotoxicity (ADCC) assays using 51Cr-labeled CEM cells, whereas polyspecific IgG were unable to induce an equivalent cytotoxicity in all instances. An increasing effect on ADCC was also observed in tests using macrophages from healthy controls to CEM coated with anti-PS IgG. These results support a potential correlation of anti-PS specificity with T-cell apoptosis in HIV-1 infection. Because PS is exteriorized by apoptotic lymphocytes, its persistence may stimulate antibodies which cooperate with macrophages in the clearance of dead cells by an enhanced ADCC mechanism. This interpretation could explain the absence of thrombophilia in HIV-1+ patients with serum elevations of antiphospholipid reactivities.


Assuntos
Anticorpos Antifosfolipídeos/imunologia , Citotoxicidade Celular Dependente de Anticorpos , Apoptose/imunologia , Infecções por HIV/imunologia , Lipídeos de Membrana/imunologia , Fosfatidilserinas/imunologia , Linfócitos T/patologia , Síndrome Antifosfolipídica/imunologia , Células Cultivadas , DNA/análise , Feminino , HIV-1 , Humanos , Imunoglobulina G/imunologia , Lúpus Eritematoso Sistêmico/imunologia , Macrófagos/imunologia , Masculino , Linfócitos T/imunologia
3.
Int J Cancer ; 65(6): 746-50, 1996 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-8631585

RESUMO

To assess the prevalence of HTLV-I and HTLV-II infections in different groups at risk for HIV-I infection, a study on 867 subjects was carried out by means of serological and PCR analyses. Serum specimens were collected from 268 intravenous drug users (IVDU), 66 homosexual men, 248 subjects with sexually transmitted diseases (STD), 105 thalassemics and 180 hemophiliacs. Sera from 3 IVDU and a sample from an STD patient were confirmed as HTLV-II seropositive; a thalassemic patient was seropositive for HTLV-I; a homosexual man, though confirmed as HTLV-I/II-seroreactive, could not be typed by serological methods. No hemophiliac was found to be HTLV-I/II-reactive. All 3 HTLV-II-seroreactive IVDU and the HTLV-I-infected thalassemic were confirmed by PCR; an additional sample from an IVDU, indeterminate by Western blot, was confirmed to be positive for HTLV-II by PCR. Subtyping of HTLV-II samples indicated the presence of II/b subtype in all 4 cases. Up to now, the reservoir for HTLV-II infection in southeastern Italy is mainly represented by IVDU, while HTLV-I infection seems to be sporadic.


Assuntos
Infecções por HIV/epidemiologia , Infecções por HTLV-I/epidemiologia , Infecções por HTLV-II/epidemiologia , Western Blotting , Soroprevalência de HIV , HIV-1 , Infecções por HTLV-I/sangue , Infecções por HTLV-II/sangue , Vírus Linfotrópico T Tipo 2 Humano/classificação , Humanos , Itália/epidemiologia , Masculino , Reação em Cadeia da Polimerase , Prevalência , Fatores de Risco
4.
Anticancer Res ; 11(1): 115-21, 1991.
Artigo em Inglês | MEDLINE | ID: mdl-2018345

RESUMO

Using L1210 and a subline resistance to chloroethylnitrosoureas (L1210/BCNU), we found that the resistance to 1-(2-chloroethyl)-1-nitrosourea (CNU) or to diethyl-1-3-(2-chloroethyl)-3-nitrosoureido ethyl phosphonate (fotemustine) can be reversed by a pretreatment with O6-methyl Guanine (O6-mGua) or temozolomide. In L1210/BCNU but not in L1210 the pretreatment with O6mGua caused an increased peak level of CNU-induced DNA-interstrand crosslinks. We then evaluated whether the resistance to BCNU could be counteracted in vivo by i.p. O6mGua treatment of L1210/BCNU bearing mice. The results were negative due to the fact that O6mGua, which was not toxic when given alone, caused a high toxicity when associated with BCNU.


Assuntos
Antineoplásicos/farmacologia , Carmustina/farmacologia , Dacarbazina/análogos & derivados , Etilnitrosoureia/análogos & derivados , Guanina/análogos & derivados , Leucemia L1210/tratamento farmacológico , Compostos de Nitrosoureia/farmacologia , Compostos Organofosforados/farmacologia , Animais , Carmustina/uso terapêutico , Ciclo Celular/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , Dacarbazina/farmacologia , Dacarbazina/uso terapêutico , Avaliação Pré-Clínica de Medicamentos , Resistência a Medicamentos , Etilnitrosoureia/farmacologia , Etilnitrosoureia/uso terapêutico , Guanina/farmacologia , Guanina/uso terapêutico , Cinética , Camundongos , Camundongos Endogâmicos DBA , Compostos de Nitrosoureia/uso terapêutico , Compostos Organofosforados/uso terapêutico , Temozolomida
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA